Insider Buying Boosts OKYO Pharma Ahead of Pivotal Phase 3 Trial

Insider Buying at OKYO Pharma Signals Confidence in a Pivotal Trial

The most recent director‑dealing filing, dated 20 July 2026, reveals that owner CERRONE GABRIELE M has purchased 25 000 shares of OKYO Pharma common stock at $1.40 per share. The transaction occurred just before the company’s Phase 3 urcosimod trial was scheduled to begin, and the trade was executed at a pre‑trade price of $1.46, representing a modest 0.07 % decline relative to the market level. At the same time, social‑media activity surrounding OKYO spiked by approximately 249 % and sentiment was highly positive (+71). These facts suggest that insiders perceive the upcoming trial as a catalyst for significant value creation, especially after the firm’s recent capital raise that has strengthened its cash position.

Implications for Investors

• Current Share Performance

• The stock has fallen 7 % in the last week and 47 % year‑to‑date.

• The 52‑week low stands at $1.34, a level that could be breached if the trial performs well.

• Cash Runway

• OKYO’s enhanced liquidity now comfortably covers the expected Phase 3 expenditures, reducing immediate financial risk.

• Signal of Confidence

• Insider purchasing—part of a broader pattern of buying by the same individual in June—acts as a bullish indicator.

• Traders should focus on enrollment milestones and regulatory feedback as these will drive future price movements.

CERRONE GABRIELE M: A Consistent Long‑Term Stakeholder

M’s transaction history demonstrates a steady accumulation of shares:

Unlike many short‑term traders, M has maintained a long‑term stake, often holding rather than selling. His buying pattern indicates a belief in OKYO’s long‑term pipeline rather than speculative gains. For investors, this pattern can be interpreted as a sign of confidence in the company’s strategy and management.

Broader Insider Activity Context

The filing also highlights purchases by other senior executives, such as options bought by the CFO and CEO at $1.85 per share. While most of these are option purchases, the collective insider buying underscores a corporate consensus that OKYO’s future prospects justify the current valuation. As the trial proceeds, continued insider participation is likely, potentially providing a cushion against market volatility.

Takeaway for Financial Professionals

The July 20 trade is an illustrative example of insider confidence coinciding with a strategic corporate milestone. It offers a useful barometer for the market’s perception of OKYO’s upcoming Phase 3 trial. For portfolio managers, the trade lends weight to a thesis that OKYO could rebound if the trial meets its endpoints. However, the company’s negative P/E ratio and low market capitalization warrant a cautious approach until clinical data are released.